<code id='9285801F00'></code><style id='9285801F00'></style>
    • <acronym id='9285801F00'></acronym>
      <center id='9285801F00'><center id='9285801F00'><tfoot id='9285801F00'></tfoot></center><abbr id='9285801F00'><dir id='9285801F00'><tfoot id='9285801F00'></tfoot><noframes id='9285801F00'>

    • <optgroup id='9285801F00'><strike id='9285801F00'><sup id='9285801F00'></sup></strike><code id='9285801F00'></code></optgroup>
        1. <b id='9285801F00'><label id='9285801F00'><select id='9285801F00'><dt id='9285801F00'><span id='9285801F00'></span></dt></select></label></b><u id='9285801F00'></u>
          <i id='9285801F00'><strike id='9285801F00'><tt id='9285801F00'><pre id='9285801F00'></pre></tt></strike></i>

          fashion

          fashion

          author:knowledge    Page View:128
          Photo illustration of a person holding smartphone with website of company Welsh, Carson Anderson and Stowe (WCAS) on screen with logo
          Physician groups backed by Welsh, Carson, Anderson & Stowe are looking to influence federal merger policy. Adobe

          Three large and growing physician groups backed by the private equity giant Welsh, Carson, Anderson & Stowe have hired a prominent lobbying firm to influence federal policy covering mergers and acquisitions.

          Over the past two weeks, United Musculoskeletal Partners, U.S. Anesthesia Partners, and U.S. Radiology Specialists each registered with Forbes Tate Partners, a lobbying shop founded by political insiders who used to work in President Bill Clinton’s administration.

          advertisement

          The doctor groups hired Forbes Tate to lobby on “issues related to health care consolidation,” according to federal lobbying disclosures. Each company and Welsh Carson did not respond to inquiries. Forbes Tate also did not respond.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          leisure time

          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more
          The new shift in health care is toward less care
          The new shift in health care is toward less care

          AdobeTheopioidcrisisrockedAmerica,bringingaddictionandoverdoseintothespotlight.Butitalsohighlightedt

          read more
          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more

          Ambulance rides for just $100? Advisers want major billing fixes

          AdobeApanelofgovernmentadvisersfinallyhasendorsedideasforCongresstosolvetheparticularlythornyproblem